Ocugen licenses OCU400 retinitis pigmentosa gene therapy rights to Roots Pharmaceutical in MENA region
Bitget2026/10/14 10:31- Ocugen signed an exclusive MENA licensing deal with Roots Pharmaceutical for OCU400, its modifier gene therapy for retinitis pigmentosa.
- Terms include an upfront license fee, up to $4 million in initial development payments, up to $255 million in sales milestones.
- Ocugen will earn 22% royalties on OCU400 net sales in the region.
- Commercial supply will be manufactured and supplied by Ocugen under a related supply agreement.
- Phase 3 liMeliGhT topline data is expected in Q1 2027, ahead of planned U.S. and European filings.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
